227 related articles for article (PubMed ID: 30936031)
1. Racial Disparities in Response to a US Food and Drug Administration Safety Communication Regarding the Use of Power Morcellation for the Treatment of Uterine Leiomyoma.
Matsushita T; Sekizawa A; Jacobs LK
J Minim Invasive Gynecol; 2020 Jan; 27(1):178-185.e1. PubMed ID: 30936031
[TBL] [Abstract][Full Text] [Related]
2. Changes in Myomectomy Practice After the U.S. Food and Drug Administration Safety Communication on Power Morcellation.
Stentz NC; Cooney LG; Sammel M; Shah DK
Obstet Gynecol; 2017 Jun; 129(6):1007-1013. PubMed ID: 28486366
[TBL] [Abstract][Full Text] [Related]
3. Minilaparotomy Versus Laparoscopic Myomectomy After Cessation of Power Morcellation: Rate of Wound Complications.
Dubin AK; Wei J; Sullivan S; Udaltsova N; Zaritsky E; Yamamoto MP
J Minim Invasive Gynecol; 2017; 24(6):946-953. PubMed ID: 28552622
[TBL] [Abstract][Full Text] [Related]
4. Association of Patient Race With Surgical Practice and Perioperative Morbidity After Myomectomy.
Stentz NC; Cooney LG; Sammel MD; Shah DK
Obstet Gynecol; 2018 Aug; 132(2):291-297. PubMed ID: 29995738
[TBL] [Abstract][Full Text] [Related]
5. Association of the U.S. Food and Drug Administration Morcellation Warning With Rates of Minimally Invasive Hysterectomy and Myomectomy.
Barron KI; Richard T; Robinson PS; Lamvu G
Obstet Gynecol; 2015 Dec; 126(6):1174-1180. PubMed ID: 26595561
[TBL] [Abstract][Full Text] [Related]
6. Change in Surgical Practice for Women With Leiomyomas After the U.S. Food and Drug Administration Morcellator Safety Communication.
Clark NM; Schembri M; Jacoby VL
Obstet Gynecol; 2017 Nov; 130(5):1057-1063. PubMed ID: 29016511
[TBL] [Abstract][Full Text] [Related]
7. In-bag manual versus uncontained power morcellation for laparoscopic myomectomy.
Zullo F; Venturella R; Raffone A; Saccone G
Cochrane Database Syst Rev; 2020 May; 5(5):CD013352. PubMed ID: 32374421
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Morcellation Techniques at the Time of Laparoscopic Hysterectomy and Myomectomy.
Meurs EAIM; Brito LG; Ajao MO; Goggins ER; Vitonis AF; Einarsson JI; Cohen SL
J Minim Invasive Gynecol; 2017; 24(5):843-849. PubMed ID: 28483536
[TBL] [Abstract][Full Text] [Related]
9. Practice Patterns and Complications of Benign Hysterectomy Following the FDA Statement Warning Against the Use of Power Morcellation.
Multinu F; Casarin J; Hanson KT; Angioni S; Mariani A; Habermann EB; Laughlin-Tommaso SK
JAMA Surg; 2018 Jun; 153(6):e180141. PubMed ID: 29641835
[TBL] [Abstract][Full Text] [Related]
10. Practice patterns and postoperative complications before and after US Food and Drug Administration safety communication on power morcellation.
Harris JA; Swenson CW; Uppal S; Kamdar N; Mahnert N; As-Sanie S; Morgan DM
Am J Obstet Gynecol; 2016 Jan; 214(1):98.e1-98.e13. PubMed ID: 26314519
[TBL] [Abstract][Full Text] [Related]
11. Hospital variation in responses to safety warnings about power morcellation in hysterectomy.
Xu X; Desai VB; Wright JD; Lin H; Schwartz PE; Gross CP
Am J Obstet Gynecol; 2021 Jun; 224(6):589.e1-589.e13. PubMed ID: 33359176
[TBL] [Abstract][Full Text] [Related]
12. Risk of morcellation of uterine leiomyosarcomas in laparoscopic supracervical hysterectomy and laparoscopic myomectomy, a retrospective trial including 4791 women.
Lieng M; Berner E; Busund B
J Minim Invasive Gynecol; 2015; 22(3):410-4. PubMed ID: 25460521
[TBL] [Abstract][Full Text] [Related]
13. Comparison of 30-day Complication Rates between Laparoscopic Myomectomy and Total Laparoscopic Hysterectomy for the Treatment of Uterine Leiomyoma in Women Older Than Age 40.
Sheyn D; Bretschnieder CE; Mahajan ST; El-Nashar S; Billow M; Ninivaggio CS
J Minim Invasive Gynecol; 2019; 26(6):1076-1082. PubMed ID: 30385429
[TBL] [Abstract][Full Text] [Related]
14. Risk of Undetected Cancer at the Time of Laparoscopic Supracervical Hysterectomy and Laparoscopic Myomectomy: Implications for the Use of Power Morcellation.
Perkins RB; Handal-Orefice R; Hanchate AD; Lin M; Paasche-Orlow MK
Womens Health Issues; 2016; 26(1):21-6. PubMed ID: 26701205
[TBL] [Abstract][Full Text] [Related]
15. Laparoscopic myomectomy and morcellation: A review of techniques, outcomes, and practice guidelines.
Glaser LM; Friedman J; Tsai S; Chaudhari A; Milad M
Best Pract Res Clin Obstet Gynaecol; 2018 Jan; 46():99-112. PubMed ID: 29078975
[TBL] [Abstract][Full Text] [Related]
16. Morcellation of occulted sarcomas during laparoscopic myomectomy and hysterectomy for patients with large fibroid uterus.
Tinelli A; Farghaly SA
Minerva Ginecol; 2018 Feb; 70(1):84-88. PubMed ID: 28975775
[TBL] [Abstract][Full Text] [Related]
17. Temporal trends in minimally invasive myomectomy before and after the US Food and Drug Administration recommendation against electric morcellation.
Pereira N; Frankel WC; Hutchinson AP; Patel HH; Mostisser C; Elias RT
Int J Gynaecol Obstet; 2017 Jun; 137(3):295-300. PubMed ID: 28218964
[TBL] [Abstract][Full Text] [Related]
18. Vaginal morcellation through the posterior cul-de-sac using an electromechanical morcellator after laparoscopic myomectomy or subtotal hysterectomy: a retrospective, case-control study.
Lee EJ; Kim DH
Surg Endosc; 2016 Nov; 30(11):4865-4870. PubMed ID: 26895917
[TBL] [Abstract][Full Text] [Related]
19. Laparoscopic Myomectomy: A Single-center Retrospective Review of 514 Patients.
Bean EM; Cutner A; Holland T; Vashisht A; Jurkovic D; Saridogan E
J Minim Invasive Gynecol; 2017; 24(3):485-493. PubMed ID: 28104498
[TBL] [Abstract][Full Text] [Related]
20. The role of power morcellation in minimally invasive gynecologic surgery.
Boudová Barbora; Richtárová Adéla; Frühauf Filip; Fischerová Daniela; Mára Michal
Ceska Gynekol; 2022; 87(4):289-294. PubMed ID: 36055791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
